|drug1318||Fixed site standard of care testing Wiki||1.00|
|drug3035||Self-collected, home-based testing Wiki||1.00|
|drug3002||Saliva test kit Wiki||1.00|
|D045169||Severe Acute Respiratory Syndrome NIH||0.04|
|D018352||Coronavirus Infections NIH||0.03|
There is one clinical trial.
This is randomized trial where households will be randomized to identify the optimal SARS-CoV-2 (COVID-19) testing modality in a population-representative sample of households in Baltimore City, Maryland. 1,386 households in Baltimore City will be randomized 1:1:1 to one of three testing modalities: 1) fixed-site standard of care testing; 2) community-based mobile van testing; or 3) self-collected home, based testing.
Description: Time (in days) from randomization to the receipt of Coronavirus infection (SARS-CoV-2) testing results by the participant.Measure: Time to receipt of SARS CoV-2 testing results Time: Measured in days from randomization up to 30 days after randomization
Description: Proportion of those who complete a survey who agree to be randomized to a SARS-CoV-2 testing modality.Measure: Acceptance of SARS CoV-2 viral testing assessed by proportion of participants who complete a survey Time: Measured from baseline survey completion to enrollment within 30 days of completion of baseline survey
Description: Uptake of SARS CoV-2 testing will be assessed by proportion of participants who are randomized and complete SARS CoV-2 testing.Measure: Uptake of SARS CoV-2 testing as assessed by proportion of participants who complete testing Time: Measured from randomization to testing completion (within 20 days of randomization)
Description: Time (In days) to completion of SARS CoV-2 testing from randomization.Measure: Time to completion of SARS CoV-2 testing Time: Measured from randomization to testing completion (Within 20 days of randomization)
Description: Time (in days) from SARS CoV-2 testing completion to the receipt of results by the participant.Measure: Time from SARS CoV-2 testing to receipt of results Time: Measured from testing completion to receipt of results (within 10 days of testing)
Data processed on January 01, 2021.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.Drug Reports MeSH Reports HPO Reports